Literature DB >> 2344169

Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations.

K S Thomson1, D A Weber, C C Sanders, W E Sanders.   

Abstract

Recent reports that members of the family Enterobacteriaceae that produce high levels of certain beta-lactamases are often resistant to ticarcillin-clavulanate prompted this study to assess the relationship between type and amount of enzyme produced and susceptibility to ticarcillin-clavulanate, piperacillin-tazobactam, and cefoperazone-sulbactam. Agar dilution MICs were determined by using 73 strains of Enterobacteriaceae that produced a single beta-lactamase that had been characterized and quantified and a beta-lactamase-negative control strain of Escherichia coli. For E. coli and Klebsiella pneumoniae, MICs of each combination increased as levels of TEM, SHV-1, or class IV enzymes increased. However, the percentage of strains that were resistant was highest for ticarcillin-clavulanate (32%), with only 18 and 6% resistant to piperacillin-tazobactam and cefoperazone-sulbactam, respectively. Strains producing PSE-1, regardless of level, were resistant or moderately susceptible to ticarcillin-clavulanate but were susceptible to piperacillin-tazobactam and cefoperazone-sulbactam. HMS-1 and OHIO-1 beta-lactamases were associated with resistance to ticarcillin-clavulanate and piperacillin-tazobactam, respectively. High levels of class IV enzymes in Klebsiella oxytoca were associated with resistance to all three combinations. These results indicate that the level and type of beta-lactamase produced by members of the family Enterobacteriaceae are important determinants of susceptibility to beta-lactam-inhibitor combinations, especially ticarcillin-clavulanate.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2344169      PMCID: PMC171654          DOI: 10.1128/AAC.34.4.622

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases.

Authors:  L Gutmann; M D Kitzis; S Yamabe; J F Acar
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

2.  Characterization of beta-lactamases in situ on polyacrylamide gels.

Authors:  C C Sanders; W E Sanders; E S Moland
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

Review 3.  Beta-lactamases.

Authors:  A A Medeiros
Journal:  Br Med Bull       Date:  1984-01       Impact factor: 4.291

4.  Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests.

Authors:  C C Sanders; J P Iaconis; G P Bodey; G Samonis
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

5.  In vitro activity of mecillinam and amoxicillin/clavulanic acid against strains of Escherichia coli producing TEM-1, Oxa-1 and chromosomal beta-lactamases.

Authors:  R Marre; E Schulz
Journal:  Arzneimittelforschung       Date:  1988-07

6.  Spread of a "Pseudomonas-specific" beta-lactamase to plasmids of enterobacteria.

Authors:  A A Medeiros; R W Hedges; G A Jacoby
Journal:  J Bacteriol       Date:  1982-02       Impact factor: 3.490

7.  Diffusion of beta-lactam antibiotics through the porin channels of Escherichia coli K-12.

Authors:  F Yoshimura; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191

8.  Variation in the potentiation of beta-lactam antibiotic activity by clavulanic acid and sulbactam against multiply antibiotic-resistant bacteria.

Authors:  K E Aldridge; C V Sanders; R L Marier
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

9.  Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads.

Authors:  M R Jacobs; S C Aronoff; S Johenning; S Yamabe
Journal:  J Antimicrob Chemother       Date:  1986-08       Impact factor: 5.790

10.  Clavulanic acid in combination with ticarcillin: an in-vitro comparison with other beta-lactams.

Authors:  A M Clarke; S J Zemcov
Journal:  J Antimicrob Chemother       Date:  1984-02       Impact factor: 5.790

View more
  15 in total

1.  Comparison of the inoculum effects of members of the family Enterobacteriaceae on cefoxitin and other cephalosporins, beta-lactamase inhibitor combinations, and the penicillin-derived components of these combinations.

Authors:  E J Goldstein; D M Citron; C E Cherubin
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.

Authors:  C C Papagiannitsis; A Loli; L S Tzouvelekis; E Tzelepi; G Arlet; V Miriagou
Journal:  Antimicrob Agents Chemother       Date:  2007-03-12       Impact factor: 5.191

3.  Comparative evaluation of the inhibitory activities of the novel penicillanic acid sulfone Ro 48-1220 against beta-lactamases that belong to groups 1, 2b, and 2be.

Authors:  L S Tzouvelekis; M Gazouli; E E Prinarakis; E Tzelepi; N J Legakis
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

4.  Propagation of TEM- and PSE-type beta-lactamases among amoxicillin-resistant Salmonella spp. isolated in France.

Authors:  C Llanes; V Kirchgesner; P Plesiat
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

5.  Molecular aspects of high-level resistance to sulbactam-cefoperazone in Klebsiella oxytoca clinical isolates.

Authors:  K Kimura; Y Arakawa; S Ohsuka; H Ito; K Suzuki; H Kurokawa; N Kato; M Ohta
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

6.  Effect of hyperproduction of TEM-1 beta-lactamase on in vitro susceptibility of Escherichia coli to beta-lactam antibiotics.

Authors:  P J Wu; K Shannon; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

7.  Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.

Authors:  D J Payne; R Cramp; D J Winstanley; D J Knowles
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  Prevalence of plasmid-mediated AmpC β-lactamases in Escherichia coli and Klebsiella pneumonia at tertiary care hospital of Islamabad, Pakistan.

Authors:  Muhammad Shafiq; Hazir Rahman; Muhammad Qasim; Najma Ayub; Shagufta Hussain; Jafar Khan; Madiha Naeem
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2013-11-21

9.  Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid.

Authors:  P Van der Auwera; V Duchateau; C Lambert; M Husson; M Kinzig; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

10.  Effect of clavulanic acid on activity of beta-lactam antibiotics in Serratia marcescens isolates producing both a TEM beta-lactamase and a chromosomal cephalosporinase.

Authors:  K Bush; R K Flamm; S Ohringer; S B Singer; R Summerill; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.